Headline
The latest stories from AHA Today.
Readmissions penalties for hospitals with the greatest share of dually eligible beneficiaries could fall by an estimated $22.4 million in fiscal year 2019, while penalties for hospitals with the least share of dually eligible patients could rise by $12.3 million.
The Centers for Medicare & Medicaid Services should evaluate state survey agency processes to ensure that all states are meeting federal requirements for investigating complaints and incidents alleging abuse in nursing homes.
The Food and Drug Administration Friday alerted hospitals and others to a temporary shortage of a tracheostomy tube used to help adult and pediatric patients breathe in health care facilities and at home.
The Federal Trade Commission will hold a public workshop June 18 in Washington, D.C., to assess the impact of certificates of public advantage on health care prices, quality, access and innovation.
In a letter to the editor, AHA today expressed concerns with a recent Modern Healthcare article presenting the findings of a study on health system consolidation and employee wages.
The Medicaid and CHIP Payment and Access Commission yesterday recommended that Congress change the definition of Medicaid shortfall to exclude costs and payments for all Medicaid-eligible patients for whom Medicaid is not the primary payer.
Updated preliminary results from studies to better understand how duodenoscopes are reprocessed in real-world settings continue to show higher than expected contamination rates after reprocessing, the Food and Drug Administration announced today.
Hospitals and health systems are facing increasing pressure from a rapidly changing landscape and competition from new market entrants looking to revolutionize health care delivery, AHA General Counsel Melinda Hatton said yesterday.
The Health Resources and Services Administration will host a webinar for applying for grants to coordinate maternal and obstetrics care in rural regions.
The House Ways and Means Committee today approved the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (H.R. 2113), AHA-supported legislation that would increase transparency with regard to prescription drug pricing.